Medexis SΑ - Translating Basic Science into Value

workkinkajouBiotechnology

Dec 5, 2012 (4 years and 10 months ago)

221 views

Member of

Group

Medexis S
Α


Translating Basic Science into Value

5
th

Venture Capital Forum

Athens, 16
-
17 June 2004

Member of

Group

Medexis Presentation: Overview


Corporate Profile & Mission


Corporate Strategy


Research & Development


Project Portfolio


Structure & Organization


Conclusions


The Gerolymatos Group

Member of

Group

Corporate Profile & Mission


Incorporated in 2002, fully owned by the Gerolymatos Group

of Companies.



Biotechnology Venture of the Group focusing on Research &
Development activities in Greece.



Medexis’s strategic objective is to identify, develop and
commercialize novel therapeutic molecules and technologies

for the treatment of critical diseases in human patients.

Member of

Group

The Gerolymatos Group


Active in the Health & Beauty Business for more than 80 years.



Product range includes: Pharmaceuticals, OTC, Diagnostics,
Veterinary, Cosmetics, and Consumer products.



Custom manufacturing & distribution for third parties.



Warehousing space 13,000 m2.



Three production plants for pharmaceuticals & cosmetics.

Member of

Group

The Gerolymatos Group


Offices in Athens, Kryoneri and Salonica.



Exports to more than 20 countries.



Subsidiaries: 6 in Greece + 6 Abroad.



>850 Employees.



2003 Sales:


165.4 million.

Member of

Group

Structure & Organization


Located in Kryoneri, Corporate Headquarters


Utilizes Corporate resources


Management & Marketing experience of the Group

Member of

Group

Structure & Organization


Extensive network of scientific advisors


100% of the budget devoted to R & D activities


Intellectual property experts

Scientific Advisory Board


Prof. Christos Stournaras (Medical School, University of Crete)


Dr. Nikos Bakopoulos (Chief Executive Officer, Aton Pharma Inc)


Dr. George Pavlakis (Head of Retroviral Section, National Cancer Institute)


Dr Aris Persidis (VP Research & Development, Upstate Inc)


Dr Basil Theofanopoulos (General Manager, Gerolymatos Inc)


The only company investing in Greek biotech research

Member of

Group

Corporate Strategy


Medexis seeks, evaluates and selectively invests in early

stage R & D projects with commercial potential that are

being developed in Greek Academic Institutions with an

aim to develop novel therapeutic treatments.



Areas of therapeutic interest include:


Cancer


CNS Diseases


Infectious Diseases


Inflammation & Wound healing

Member of

Group

Corporate Strategy


Development of product candidates from an early pre
-
clinical to
a late
-
preclinical stage (IND) or phase I before partnering with a
strategic ally (out
-
licensing)


Strategic contacts and alliances with prominent Greek Research
Institutes allow for identification of interesting IP


Assignment of the commercial exploitation of the invention in
exchange to royalties on future profits (in
-
licensing)


R & D funding according to specific scientific milestones


Development of IP portfolio

Member of

Group

Research & Development


Develop therapeutic molecules from an early pre
-
clinical to a late
pre
-
clinical stage (IND) or phase I.


Out


license project to a strategic partner(s) in exchange of cash
down payments, milestone payments and royalties.

15

10

5

Idea

Drug

12
-
15 Years

Discovery

Drug Evaluation

Full Development

Phase I

Phase II

Phase III

0

Out
-
Licensing

In
-
Licensing

Member of

Group

Research & Development

15

10

5

Idea

Drug

12
-
15 Years

Discovery

Drug Evaluation

Full Development

Phase I

Phase II

Phase III

0

Out
-
Licensing

In
-
Licensing


Scientific Innovation & Excellence


IP Evaluation and Patentability


Commercial Potential/Business Risk


Regulatory

Member of

Group

Project Portfolio

Gerolab Project


Pharmaceutical formulations comprising labdanes for the treatment of

tumors and leukemia.

CastBSA

Project


Steroid
-
protein conjugates for the treatment of tumors and hematological
malignancies.

Angiomed

Project


Novel angiogenic molecules for the treatment of cancer and ophthalmic
disorders.

Member of

Group

Project Portfolio

Gerolab Project


R & D Status:

Proof
-
of
-
concept, colon cancer


Patent Status
:

GR 1003509, US 6,652,877, AU 773462



PCT/GR00/00033 (WO 01/34116) pending in

EPO, Canada, Japan

CastBSA

Project


R & D Status:

Proof
-
of
-
concept, prostate cancer


Patent Status
:

GR 1004274



PCT/IB03/02785 (WO 04/06966) pending for

122
countries

Angiomed

Project


R & D Status:

Proof
-
of
-
concept, neuroblastomas


Patent Status
:

GR
20030100319,
GR
20030100362
, pending



US 60/493.975, US 60/502.047
,
pending

Member of

Group

Project Portfolio

Helixplast



Medical Device of class IIb based on Helixderm®, a pharmaceutical
product of herbal origin approved by EOF for wound healing.



CE Mark



Launch in Greece & Europe within 2005

Member of

Group

Conclusions


Medexis focuses on early stage biotechnology projects aiming at the
development of novel therapeutic applications.



Medexis promotes technology transfer from the Academic Institutions
to the industry financing Research & Development and developing the
product IP portfolio.



Medexis’s strategic goal is to develop product candidates to a late pre
-
clinical stage (IND) or phase I and collaborate with a strategic partner for
further development/clinical testing of the products.



Medexis’s portfolio consists of three anti
-
cancer projects currently at
the proof
-
of
-
concept stage in animal models of cancer.

Member of

Group

Medexis S
Α


Translating Basic Science into Value

5
th

Venture Capital Forum

Athens, 16
-
17 June 2004

Kostantinos Alevizopoulos Ph.D.

Medexis SA

contact@medexis
-
biotech.com